

Notification of attendance and form for advance voting

The form must be received by Egetis Therapeutics no later than April 29, 2024.

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Egetis Therapeutics AB (publ), Reg. No. 556706–6724 at the annual general meeting on May 6, 2024. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): The undersigned solemnly declare that the enclosed power of attorney corresponds to the original and has not been revoked.

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

Instructions

- Complete all the requested information above
- Select the preferred voting options below
- Print, sign and send the form by post to Egetis Therapeutics, Klara Norra Kyrkogata 26, SE-111 22, Stockholm, Sweden or via e-mail to info@egetis.com
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign
- If the shareholder votes by proxy, a proxy shall be enclosed to the form. If the shareholder is a legal entity, a certificate of incorporation or an equivalent certificate of authority should be enclosed to the form

A shareholder whose shares have been registered in the name of a bank or securities institute must register its shares in its own name to vote. Instructions for this is included in the notice convening the annual general meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (*i.e.* the advance vote in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented.

The advance voting form, together with any enclosed authorisation documentation, shall be provided to Egetis Therapeutics no later than April 29, 2024. An advance vote can be withdrawn up to and including April 29, 2024 by contacting Egetis Therapeutics via e-mail to info@egetis.com.

One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by Egetis Therapeutics will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. If a shareholder has voted in advance and attends the annual general meeting in person or through a proxy, the advance vote is still valid except to the extent the shareholder participates in a voting procedure at the annual general meeting or otherwise withdraws its casted advance vote. If the shareholder chooses to participate in a voting at the annual general meeting, the vote cast will replace the advance vote with regard to the relevant item on the agenda.

Note that the advance vote does not constitute a notification to participate in the annual general meeting at the venue in person or through proxy. Instructions for shareholders who wish to participate in the annual general meeting at the venue in person or represented by a proxy are included in the notice convening the annual general meeting.

For the complete proposals, kindly refer to the notice convening the annual general meeting and the company's website www.egetis.com.

For information on how your personal data is processed, see the integrity policy that is available at <https://www.egetis.com> and at Euroclear's website, www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual general meeting in Egetis Therapeutics AB (publ) on May 6, 2024

The options below comprise the submitted proposals included in the notice convening the annual general meeting and are held available on the company's website.

2. Election of chairman of the general meeting
2.1 Dain Hård Nevonen Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Determination of whether the annual general meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
8.a) Resolution on adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
8.b) Resolution on allocation of the Company's result pursuant to the adopted balance sheet of the parent company Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c) Resolution on discharge from liability for the members of the Board of Directors and the Chief Executive Officer
8.c).1 Thomas Lönngren, chairman Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c).2 Mats Blom, board member Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c).3 Gunilla Osswald, board member Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c).4 Behshad Sheldon, board member Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c).5 Elisabeth Svanberg, board member Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c).6 Peder Walberg, board member Yes <input type="checkbox"/> No <input type="checkbox"/>
8.c).7 Nicklas Westerholm, Chief Executive Officer Yes <input type="checkbox"/> No <input type="checkbox"/>

9. Resolution of the number of members of the Board of Directors and the number of auditors
9.1 Number of members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
9.2 Number of auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
10. Resolution on the remuneration to the members of the Board of Directors and the auditor
10.1 Remuneration to the members of the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
10.2 Remuneration to the auditor Yes <input type="checkbox"/> No <input type="checkbox"/>
11. Election of Board of Directors
11.1 Thomas Lönngren, board member (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.2 Mats Blom, board member (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.3 Gunilla Osswald, board member (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.4 Behshad Sheldon, board member (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.5 Elisabeth Svanberg, board member (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.6 Peder Walberg, board member (re-election) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.7 Mats Blom, chairman (new election) Yes <input type="checkbox"/> No <input type="checkbox"/>
12. Election of auditor Yes <input type="checkbox"/> No <input type="checkbox"/>
13. Resolution regarding instructions to the Nomination Committee Yes <input type="checkbox"/> No <input type="checkbox"/>
14. Resolution on approval of the remuneration report for the financial year 2023 Yes <input type="checkbox"/> No <input type="checkbox"/>

15. Resolution to amend the articles of association Yes <input type="checkbox"/> No <input type="checkbox"/>
16. Resolution in order to adopt a long-term incentive program for the Company's management and key personnel, including:
16.a) Adoption of a long-term incentive program for the Company's management and key personnel Yes <input type="checkbox"/> No <input type="checkbox"/>
16.b)(i) Introduction of a new class of shares by amending the articles of association Yes <input type="checkbox"/> No <input type="checkbox"/>
16.b)(ii) Authorization for the Board of Directors to resolve to issue new class C shares Yes <input type="checkbox"/> No <input type="checkbox"/>
16.b)(iii) Authorization for the Board of Directors to resolve on repurchase of class C shares Yes <input type="checkbox"/> No <input type="checkbox"/>
16.b)(iv) Transfer of own ordinary shares to participants and in the market Yes <input type="checkbox"/> No <input type="checkbox"/>
16.c) Equity swap agreement with a third party Yes <input type="checkbox"/> No <input type="checkbox"/>
17. Resolution on amendment of previously outstanding long-term incentive programs adopted in 2021, 2022 and 2023, including:
17.a) Amendment of the terms and conditions of the previously outstanding long-term incentive programs adopted in 2021, 2022 and 2023 Yes <input type="checkbox"/> No <input type="checkbox"/>
17.b) Authorization for the Board of Directors to resolve to issue new class C shares Yes <input type="checkbox"/> No <input type="checkbox"/>
17.c) Authorization for the Board of Directors to resolve on repurchase of class C shares Yes <input type="checkbox"/> No <input type="checkbox"/>
17.d) Transfer of own ordinary shares to participants and in the market Yes <input type="checkbox"/> No <input type="checkbox"/>
18. Resolution on authorization for issuances Yes <input type="checkbox"/> No <input type="checkbox"/>